Stock HNSA HANSA BIOPHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Company Hansa Biopharma AB

Equities

HNSA

SE0002148817

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:58 2024-04-26 am EDT 		5-day change 1st Jan Change
27.32 SEK +0.44% Intraday chart for Hansa Biopharma AB -6.76% +4.27%
Apr. 18 Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024
Apr. 18 Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Business Summary

Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.

Number of employees: 166

Sales per Business

SEK in Million2022Weight2023Weight Delta
Antibody-cleaving Enzyme Technology Platform
100.0 %
155 100.0 % 134 100.0 % -13.22%

Sales per region

SEK in Million2022Weight2023Weight Delta
Europe (excluding Sweden)
79.6 %
86 55.4 % 107 79.6 % +24.66%
North America
20.4 %
64 41.6 % 27 20.4 % -57.34%

Managers

Managers TitleAgeSince
Søren Tulstrup CEO
 Chief Executive Officer 59 18-03-19
Hitto Kaufmann CTO
 Chief Tech/Sci/R&D Officer 53 Nov. 30
Achim Kaufhold CTO
 Chief Tech/Sci/R&D Officer 66 20-05-28
Stephanie Kenney
- -
Klaus Sindahl IRC
 Investor Relations Contact - 19-04-28
Matthew Shaulis PRN
 Corporate Officer/Principal - 23-03-15
Max Sakajja PRN
 Corporate Officer/Principal 43 16-12-31
Anne Lanner HRO
 Human Resources Officer 55 19-01-17
Vincenza Nigro PRN
 Corporate Officer/Principal - 18-09-16
Magnus Korsgren PRN
 Corporate Officer/Principal 55 21-03-31

Members of the board

Members of the board TitleAgeSince
Anders Gersel Pedersen BRD
 Director/Board Member 73 18-05-28
Peter Nicklin CHM
 Chairman 61 22-06-29
Mats Blom BRD
 Director/Board Member 59 19-05-21
Eva Nilsagård BRD
 Director/Board Member 60 19-05-21
Hilary Malone BRD
 Director/Board Member 59 21-05-11
Andreas Eggert BRD
 Director/Board Member 56 18-05-28

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 2,362,445 0 2,362,445 ( 100.00 %) 88.64 %
Stock B 1 52,443,962 48,580,000 ( 92.63 %) 0

Shareholders

NameEquities%Valuation
Redmile Group LLC
23.18 %
12,209,214 23.18 % 33 M kr
Braidwell LP
11.61 %
6,112,950 11.61 % 17 M kr
Max Mitteregger Kapitalförvaltning AB
4.260 %
2,243,867 4.260 % 6 M kr
Fjärde AP-fonden
4.191 %
2,207,397 4.191 % 6 M kr
Bengt Ågerup
4.092 %
2,155,379 4.092 % 6 M kr
Thomas Olausson
3.640 %
1,917,000 3.640 % 5 M kr
AVANZA BANK HOLDING AB
3.514 %
1,850,701 3.514 % 5 M kr
Tredje AP-fonden
2.638 %
1,389,650 2.638 % 4 M kr
Handelsbanken Fonder AB
1.669 %
879,183 1.669 % 2 M kr
Theodor Jeansson
1.633 %
860,000 1.633 % 2 M kr
NameEquities%Valuation
HANSA BIOPHARMA AB
100.00 %
2,598,012 100.00 % 7 M kr

Holdings

NameEquities%Valuation
HANSA BIOPHARMA AB
100.00%
 2,598,012 100.00% 7,070,516 $

Company contact information

Hansa Biopharma AB

Scheelevägen 22

223 63, Lund

+46 46 16 56 70

http://www.hansabiopharma.com
address Hansa Biopharma AB(HNSA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Ratings for Hansa Biopharma AB

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
27.32 SEK
Average target price
105 SEK
Spread / Average Target
+284.33%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
HANSA BIOPHARMA AB Stock Hansa Biopharma AB
+4.27% 137M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. HNSA Stock
  4. Company Hansa Biopharma AB